Stryker Corp - SYK STOCK NEWS

Stryker (NYSE:SYK) has scheduled its first quarter fiscal year 2025 financial results announcement for Thursday, May 1, 2025. The company will release a press release containing summary financial information at approximately 4:05 p.m. ET, covering the quarter ending March 31, 2025.

A webcast to discuss the Q1 2025 results will be held at 4:30 p.m. ET on the same day. The webcast will be accessible through Stryker's Events & Presentations webpage, with an archive available on the company's website two hours after the live call concludes.

Stryker (NYSE: SYK) has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, , which will operate under the newly formed VB Spine, . The strategic divestment aims to enhance Stryker's focus and enable investments in areas with greater innovation and growth potential.

As part of the agreement, VB Spine will have exclusive access to Mako Spine and Copilot technologies for spine procedures. Stryker maintains its presence in the spine sector through its Interventional Spine, Neurotechnology, and Enabling Technologies businesses, along with a strategic partnership with VB Spine.

The transaction's international component will be executed in phases, with transfers to VB Spine in certain markets pending legal, regulatory, and employee consultation requirements.

Stryker (NYSE:SYK) has nominated Emmanuel "Manny" Maceda to its board of directors, with the election scheduled for the Annual Meeting of Shareholders on May 8, 2025. Maceda brings over 30 years of experience in leading organizations and advising executives on corporate transformations.

Maceda currently serves as Chairman of Bain & Company, following his role as Worldwide Managing Partner and CEO from 2018 to 2024. During his leadership, he drove Bain's global transformation across 50+ offices, strengthening digital capabilities and expanding sustainability focus. Since joining Bain in 1989, he has held various senior leadership positions and advised CEOs on strategy, growth, and organizational effectiveness.

Stryker (NYSE:SYK) has scheduled its 2025 Annual Meeting of Shareholders for Thursday, May 8, 2025, at 9:30 a.m. Eastern Time. The meeting will be conducted virtually via the internet.

Shareholders can access the webcast, including audio and slide presentation, through the company's Investor Relations page at www.investorevents.stryker.com. For audio-only participation, attendees can dial (877) 328-2502 (U.S.) or (412) 317-5419 (International) and request the "Stryker Annual Meeting."

A recording will be available from 10:30 a.m. ET on May 9, 2025, at www.virtualshareholdermeeting.com/SYK2025 until the 2026 proxy statement filing.

Stryker (NYSE: SYK) unveiled significant advancements in its Mako SmartRobotics™ technology at AAOS 2025 Annual Meeting in San Diego. The company highlighted that Mako has achieved over 1.5 million procedures globally across 45 countries.

Key announcements include:

• Introduction of Mako Total Hip with Advanced Primary and Revision, featuring first-to-market robotic hip revision capability
• Launch of fourth-generation Mako 4 system, offering multiple applications across Total Hip, Total Knee, Partial Knee and Spine procedures
• Integration of fourth-generation Q Guidance System
• Expansion into Mako Spine and Mako Shoulder applications

The company completed initial Mako Spine cases in October and plans full U.S. commercial launch in second half of 2025. Mako Shoulder, introduced late last year, remains in market release through 2025.

Inari Medical, now part of Stryker (NYSE: SYK), has launched the Artix™ Thrombectomy System, a new medical device designed for peripheral arterial thrombectomy. The system combines aspiration and mechanical thrombectomy capabilities to address arterial blood clots in the legs, which are life- and limb-threatening emergencies.

The Artix system features a dual mechanical thrombectomy and aspiration toolkit, capable of removing acute to chronic clots in a single session. It includes an 8 Fr. low-profile sheath available in 65cm and 90cm lengths, and an innovative over-the-wire mechanical element. The system also incorporates a covered nitinol mesh funnel to minimize clot migration risk.

The first commercial case using Artix was performed by Dr. Jonathan Bowman at Norwalk Hospital on October 19, 2024. The device aims to overcome limitations of existing therapies, which can lead to ineffective clot retrieval, significant blood loss, vessel trauma, and high rates of lytic use.

Stryker (NYSE:SYK) has launched its latest personal protective equipment, the Steri-Shield 8 personal protection system. The new system features a customizable helmet with three points of contact and three toga choices, representing an evolution in healthcare PPE technology.

Key improvements include a helmet with three points of securement, a ponytail accommodation path, enhanced visibility with a brighter light and 22% wider field of vision compared to previous versions. The system also features a redesigned fan targeting the front and back of users' necks, a sleeker battery, and a more efficient charging station.

The three toga styles offer AAMI level 4 (2012) protection in all critical zones, providing maximum fluid and microbial barrier protection for healthcare professionals.

Stryker (NYSE:SYK) has launched the Sync Badge, a hands-free wearable communication device designed to enhance collaboration in patient care environments. The device allows care team members to use voice commands to connect with colleagues across units and roles.

Key features include:

• Voice activation using 'Okay Vocera' wake word
• Dedicated panic button for emergency assistance
• Do Not Disturb mode with urgent call breakthrough
• Integration with EHR, nurse call systems, and medical devices

The launch aims to address ongoing nursing shortages and unpredictable healthcare environments by simplifying workflows and improving communication efficiency.

Stryker (NYSE: SYK) has completed the acquisition of Inari Medical, a company specializing in venous thromboembolism (VTE) clot removal solutions. The acquisition provides Stryker entry into the fast-growing peripheral vascular segment. The transaction was completed through a cash tender offer at $80.00 per share, with approximately 81.69% (48,504,444 shares) of Inari's outstanding shares validly tendered.

Inari's product portfolio, which includes the FlowTriever System for pulmonary embolism treatment and the ClotTriever System for peripheral vessel thrombectomy, complements Stryker's Neurovascular business. Following the merger completion on February 19, 2025, Inari has become a wholly owned subsidiary of Stryker and will be delisted from the Nasdaq Global Select Market.